Log In Sign up
The largest database of trusted experimental protocols

Pde3a

Manufactured by BPS Biosciences
Visit Supplier
Sourced in United States

PDE3A is a laboratory product offered by BPS Biosciences. It is a recombinant human phosphodiesterase 3A enzyme. Phosphodiesterases are a family of enzymes that play a role in the regulation of cyclic nucleotide signaling pathways.

Automatically generated - may contain errors

Lab products found in correlation

Pde4d, by BPS Biosciences (2 mentions) Pde7a, by BPS Biosciences (2 mentions) Pde1a, by BPS Biosciences (2 mentions) Pde10a, by BPS Biosciences (1 mentions) Lance ultra camp assay kit, by PerkinElmer (1 mentions) Envision multilable reader, by PerkinElmer (1 mentions) Pde4b, by BPS Biosciences (1 mentions) Pde3b, by BPS Biosciences (1 mentions) Infinite m1000, by Tecan (1 mentions) Magellan 6, by Tecan (1 mentions)

3 protocols using pde3a

1

Enzymatic Activity Measurement of Phosphodiesterases

Check if the same lab product or an alternative is used in the 5 most similar protocols
The enzymatic activity of the purified catalytic domain of PDE4D, PDE5A, PDE7A, PDE9A, and PDE10A, and full-length PDE1A, PDE2A, PDE3A, PDE6C, PDE8A, and PDE11A, purchased from BPS Bioscience (San Diego, CA, USA), was performed by determining the biochemical hydrolysis of [3H]-cAMP or [3H]-cGMP into [3H]-AMP or [3H]-GMP, respectively, using the scintillation proximity assay (SPA) as described previously [25] (link). The enzymatic activities in RAW264.7 cells and skin biopsies were normalized to the concentration of total proteins.
Li H., Zhang X., Xiang C., Feng C., Fan C., Liu M., Lu H., Su H., Zhou Y., Qi Q., Xu Y, & Tang W. (2021). Identification of phosphodiesterase-4 as the therapeutic target of arctigenin in alleviating psoriatic skin inflammation. Journal of Advanced Research, 33, 241-251.
+ Open protocol
+ Expand
2

Enzyme Inhibition Assay for PDE Enzymes

Check if the same lab product or an alternative is used in the 5 most similar protocols
The enzyme inhibition assay was performed against human PDE enzymes (PDE1A, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, and PDE7A; BPS Biosciences, San Diego, CA, United States) according to the manufacturer’s instructions (LANCE Ultra cAMP assay kit; Perkin Elmer, United States). In each well, 5 μl of 3 nM cAMP, 2.5 μl of PDE enzyme (0.1 ng/well), and 2.5 μl of inhibitor solution were added, and incubated at 37°C for 1 h. After incubation, 5 μL each of Eu-cAMP and ULight-anti-cAMP detection reagent supplemented with 1 mM of IBMX were added. The reaction mixture was incubated at 37°C for 1 h. After incubation, emission signals were collected at 665 nm using EnVision Multilable Reader (Perkin Elmer, United States).
Purushothaman B., Arumugam P, & Song J.M. (2018). A Novel Catecholopyrimidine Based Small Molecule PDE4B Inhibitor Suppresses Inflammatory Cytokines in Atopic Mice. Frontiers in Pharmacology, 9, 485.
+ Open protocol
+ Expand
3

Fluorescence Polarization Assay for PDE3 Inhibition

Check if the same lab product or an alternative is used in the 5 most similar protocols
A commercial fluorescence polarization assay was performed using
recombinant PDE3A and PDE3B by BPS Bioscience. Compounds were tested in
duplicate at 9 concentrations in a half-logarithmic dilution series (top
concentration of 10 μM) with final DMSO concentration of 1%. The
enzymatic reactions were conducted at room temperature for 60 minutes in a 50
μl mixture containing PDE assay buffer, 100 nM FAM-cAMP, a PDE enzyme and
the test compound. After the enzymatic reaction, 100 μl of a binding
solution (1:100 dilution of the binding agent with the binding agent diluent)
was added to each mix, and the reaction was performed at room temperature for 15
minutes. Fluorescence intensity was measured at an excitation of 485 nm and an
emission of 528 nm using a Tecan Infinite M1000 microplate reader. Fluorescence
intensity was converted to fluorescence polarization using the Tecan Magellan 6
software.
Corsello S.M., Nagari R.T., Spangler R.D., Rossen J., Kocak M., Bryan J.G., Humeidi R., Peck D., Wu X., Tang A.A., Wang V.M., Bender S.A., Lemire E., Narayan R., Montgomery P., Ben-David U., Garvie C.W., Chen Y., Rees M.G., Lyons N.J., McFarland J.M., Wong B.T., Wang L., Dumont N., O’Hearn P.J., Stefan E., Doench J.G., Harrington C.N., Greulich H., Meyerson M., Vazquez F., Subramanian A., Roth J.A., Bittker J.A., Boehm J.S., Mader C.C., Tsherniak A, & Golub T.R. (2020). Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nature cancer, 1(2), 235-248.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!